---
title: "Roche Completes USD300 Million Shanghai Plant, Eyes Local Production of Eye Drug by 2028"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306112075.md"
description: "Roche has completed construction of a USD300 million biopharmaceutical manufacturing facility in Shanghai. This marks its second innovative drug base in China and aims to localize production of faricimab (Vabysmo) by mid-2028, the first such large-molecule antibody production by a multinational in China. The company plans to submit nearly 20 new products for approval in China over the next two to five years."
datetime: "2026-11-19T11:37:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306112075.md)
  - [en](https://longbridge.com/en/news/306112075.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306112075.md)
generator: "portal-rs"
---

# Roche Completes USD300 Million Shanghai Plant, Eyes Local Production of Eye Drug by 2028

(Yicai) Nov. 19 -- Roche has finished construction of a CNY2 billion (USD300 million) biopharmaceutical manufacturing facility in Shanghai, marking a major step in the Swiss pharmaceutical giant’s efforts to expand local production of innovative medicines in China.

The facility, which is Roche’s second innovative drug manufacturing base in the country, is expected to begin local production of faricimab, an injectable treatment for retinal diseases such as macular degeneration, by mid-2028 with sterile filling operations scheduled to start by the end of 2030, the Basel-based company said yesterday.

This will mark the first time a multinational pharmaceutical company has achieved localized production of large-molecule antibody-based biopharmaceuticals in China, it added.

Faricimab, which is marketed as Vabysmo, is the world's first bispecific antibody that targets both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2), helping to inhibit abnormal blood vessel growth while improving vascular stability. The drug was approved in China in December 2023 and added to the National Reimbursement Drug List in 2025.

Roche became the first multinational pharmaceutical firm to move into the Zhangjiang High-Tech Park in Shanghai in 1994. After 30 years of development, Roche now has 28 products on the market in China, covering eight fields such as oncology, infectious diseases, neuroscience and ophthalmology, according to its website.

Over the next two to five years, Roche plans to submit nearly 20 new products with more than 40 new indications for regulatory approval in China, it said. These will cover a range of therapeutic areas, including oncology and hematology, neuroscience, immunology, ophthalmology as well as cardiovascular, renal and metabolic diseases.

Going forward, Roche will use the new manufacturing facility to further prioritize local production and accelerate the rollout of more locally manufactured innovative medicines in China, including treatments for breast cancer, lung cancer and infectious diseases, it added.

Editors: Dou Shicong, Kim Taylor

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Roche Holding (SWX:ROP) Wins FDA Clears In Breast Cancer And Kidney Disease](https://longbridge.com/en/news/306181148.md)
- [Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies](https://longbridge.com/en/news/305863519.md)
- [FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer | RHHBY Stock News](https://longbridge.com/en/news/305729180.md)
- [Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy | RHHBY Stock News](https://longbridge.com/en/news/305621107.md)
- [CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for systemic lupus erythematosus (SLE) | RHHBY Stock News](https://longbridge.com/en/news/305456718.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**